Steven Nissen, MD, Discusses Historic Bempedoic Acid Labeling for CV Risk Reduction
CLEAR Outcomes PI Steven Nissen, MD, links findings from the pivotal trial with labeling updates that make bempedoic acid the only nonstatin agent approved to reduce CV risk.
Steven Nissen, MD, spoke with Patient Care about the findings from the landmark CLEAR Outcomes trial that support the new labeling for bempedoic acid as the only non-statin drug indicated to reduce cardiovascular risk. Nissen is Chief Academic Officer, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH and the primary investigator for the bempedoic acid and bempedoic acid plus ezetimibe clinical trial program.
This is an excerpt from a longer interview; additional content will be available shortly.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Recent Videos
Related Content
